EG-COVID / Eyegene - LARVOL DELTA

Telehealth and cancer care delivery: An updated real-world analysis of the impact of telehealth on patient access and treatment utilization at a comprehensive cancer center. (ASCO 2025) - "We selected 3 disease groups with varying telehealth use – breast (low), GI (medium), and GU (high) – allowing us to better control for external factors (eg COVID)... Among 3 disease groups with varying telehealth use, pt volume increased in all groups, while the % of pts receiving tx at our center decreased. This suggests that providers may be providing collaborative care while pts receive care locally. In regression analyses, higher % of IP medical onc visits was positively associated with receiving infusions, highlighting the importance of IP visits during active medical onc tx."

Clinical • Real-world • Real-world evidence • Oncology

Can Brachytherapy dose be safely de-escalated in selected patients of locally advanced cervical cancer in the era of IGABT? (ESTRO 2025) - "Based on our institutional experience, a dose schedule of 9Gy x 2 fractions is still used in select patients with small HRCTV volumes, advanced age, severe co-morbidities and situations (eg COVID pandemic) necessitating abbreviated treatment In this study, we report the dosimetric and clinical outcomes of patients of LACC treated with 9Gy x 2 fractions schedule using image guided adaptive brachytherapy... Brachytherapy dose can be safely de-escalated in selected patients of LACC with limited HRCTV at brachytherapy. The results of the study are particularly relevant to resource constrained settings and can form the basis for the design of large randomised trials for brachytherapy dose de-escalation in the future."

Clinical • Metastases • Cervical Cancer • Novel Coronavirus Disease • Oncology • Solid Tumor

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers (clinicaltrials.gov) - P1/2 | N=67 | Completed | Sponsor: EyeGene Inc. | Active, not recruiting ➔ Completed | Trial completion date: Aug 2024 ➔ Feb 2025

Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers (clinicaltrials.gov) - P1/2 | N=67 | Active, not recruiting | Sponsor: EyeGene Inc. | Trial completion date: Apr 2024 ➔ Aug 2024 | Trial primary completion date: Dec 2023 ➔ Aug 2024

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease